Celltrion Company Description

Celltrion, Inc., together with its subsidiaries, develops and produces drugs based on proteins for the treatment of oncology in South Korea.

The company markets biopharmaceuticals; generic pharmaceuticals; and covid-19 test kits. Its antibody biosimilar pipeline includes CT-P44 that is in phase 3 clinical trial for the treatment of multiple myeloma; CT-P51, which is in phase 3 clinical trial for the treatment of Melanoma, lung cancer; CT-P53, which is in phase 3 clinical trial for the treatment of multiple sclerosis; and CT-P55 that is in phase 3 clinical trial for the treatment of Psoriasis.

Celltrion, Inc. was founded in 2002 and is headquartered in Incheon, South Korea.

Celltrion, Inc.

Country	South Korea
Founded	2002
Industry	Biotechnology
Sector	Healthcare
Employees	2,391

Contact Details

Address: 23 Academy-ro Incheon South Korea
Phone	82 3 2850 5000
Website	celltrion.com

Stock Details

Ticker Symbol	068270
Exchange	Korea Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	KRW
ISIN Number	KR7068270008
SIC Code	2836

Key Executives

Name	Position
Jin-seok Seo	Co-Chief Executive Officer and Inside Co-Chairman of the Board
Woo-Sung Kee	Co-Chief Executive Officer and Internal Director
Hyong-Gi Kim	Chief Executive Officer and Internal Director
Stephen Yeum	Founder
Min-Cheol Shin	Director of Finance
Ji-Hoon Choi	Director of Legal Affairs